Recent News

June 27, 2022

MOUNTAIN VALLEY MD SUCCESSFULLY COMPLETES PRECLINICAL PHARMACOKINETIC STUDY FOR SOLUVEC™ 1%

View CEO Update

June 27, 2022

MOUNTAIN VALLEY MD SUCCESSFULLY COMPLETES PRECLINICAL PHARMACOKINETIC STUDY FOR SOLUVEC™ 1%

View Media Release

April 28, 2022

MOUNTAIN VALLEY MD HOLDINGS PROVIDES BUSINESS UPDATE

View CEO Update

April 28, 2022

MOUNTAIN VALLEY MD HOLDINGS PROVIDES BUSINESS UPDATE

View Media Release

March 16, 2022

MOUNTAIN VALLEY MD HOLDINGS APPOINTS DR. ELIZABETH NORTON TO ADVISORY ROLE TO SUPPORT KEY QUICKSOME™ VACCINE AND COLD CHAIN PROJECTS

View CEO Update

March 16, 2022

MOUNTAIN VALLEY MD HOLDINGS APPOINTS DR. ELIZABETH NORTON TO ADVISORY ROLE TO SUPPORT KEY QUICKSOME™ VACCINE AND COLD CHAIN PROJECTS

View Media Release

January 28, 2022

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES RESTRICTED SHARE UNIT PLAN, RSU GRANT AND STOCK OPTION GRANT

View CEO Update

January 28, 2022

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES RESTRICTED SHARE UNIT PLAN, RSU GRANT AND STOCK OPTION GRANT

View Media Release

November 2, 2021

MOUNTAIN VALLEY MD HOLDINGS COMPLETES LICENSING AGREEMENT WITH RED WHITE AND BLOOM BRANDS INC.

View CEO Update

November 2, 2021

MOUNTAIN VALLEY MD HOLDINGS COMPLETES LICENSING AGREEMENT WITH RED WHITE AND BLOOM BRANDS INC.

View Media Release

September 29, 2021

MOUNTAIN VALLEY MD HOLDINGS PROVIDES BUSINESS UPDATE, RESULTS OF SHAREHOLDER MEETING

View CEO Update

September 29, 2021

MOUNTAIN VALLEY MD HOLDINGS PROVIDES BUSINESS UPDATE, RESULTS OF SHAREHOLDER MEETING

View Media Release

September 29, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES LETTER OF INTENT WITH RED WHITE AND BLOOM BRANDS INC.

View CEO Update

September 29, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES LETTER OF INTENT WITH RED WHITE AND BLOOM BRANDS INC.

View Media Release

September 15, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES VOLUNTARY RETRACTION OF A REPORTED DATA SET, NO MATERIAL CHANGE TO BUSINESS PLAN ANTICIPATED

View CEO Update

September 15, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES VOLUNTARY RETRACTION OF A REPORTED DATA SET, NO MATERIAL CHANGE TO BUSINESS PLAN ANTICIPATED

View Media Release

September 9, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES ANNUAL SHAREHOLDER MEETING

View CEO Update

September 9, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES ANNUAL SHAREHOLDER MEETING

View Media Release

August 26, 2021

MOUNTAIN VALLEY MD HOLDINGS TO GRADUATE TO OTCQX BEST MARKET, UPDATES BROADER UP-LISTING STRATEGY

View CEO Update

August 26, 2021

MOUNTAIN VALLEY MD HOLDINGS TO GRADUATE TO OTCQX BEST MARKET, UPDATES BROADER UP-LISTING STRATEGY

View Media Release

August 3, 2021

MOUNTAIN VALLEY MD APPOINTS CHIEF MEDICAL OFFICER

View CEO Update

August 3, 2021

MOUNTAIN VALLEY MD APPOINTS CHIEF MEDICAL OFFICER

View Media Release

July 15, 2021

MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS, STOCK OPTION GRANT AND PROVIDES UPLISTING UPDATE

View CEO Update

July 15, 2021

MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS, STOCK OPTION GRANT AND PROVIDES UPLISTING UPDATE

View Media Release

July 7, 2021

MOUNTAIN VALLEY MD ANNOUNCES RESULTS FROM COLD CHAIN STORAGE EVALUATION OF NOVEL QUICKSOME™ TECHNOLOGY

View CEO Update

July 7, 2021

MOUNTAIN VALLEY MD ANNOUNCES RESULTS FROM COLD CHAIN STORAGE EVALUATION OF NOVEL QUICKSOME™ TECHNOLOGY

View Media Release

June 24, 2021

MOUNTAIN VALLEY MD PROVIDES UPDATE ON KEY STRATEGIC INITIATIVES: PATENT AWARD, FDA COLLABORATIVE RESEARCH AGREEMENT, COLD CHAIN, DOSE SPARING, HUSBANDRY, ONCOLOGY, TB, CANNABIS

View CEO Update

June 24, 2021

MOUNTAIN VALLEY MD PROVIDES UPDATE ON KEY STRATEGIC INITIATIVES: PATENT AWARD, FDA COLLABORATIVE RESEARCH AGREEMENT, COLD CHAIN, DOSE SPARING, HUSBANDRY, ONCOLOGY, TB, CANNABIS

View Media Release

May 21, 2021

MOUNTAIN VALLEY MD TO HOST LIVE, VIRTUAL TOWN HALL Q&A SESSION WITH COMPANY PRESIDENT & CEO, DENNIS HANCOCK

View CEO Update

May 21, 2021

MOUNTAIN VALLEY MD TO HOST LIVE, VIRTUAL TOWN HALL Q&A SESSION WITH COMPANY PRESIDENT & CEO, DENNIS HANCOCK

View Media Release

May 18, 2021

MOUNTAIN VALLEY MD RECEIVES SUCCESSFUL RESULTS FROM BSL-4 COVID-19 CLEARANCE TRIAL ON THREE VARIANTS TESTED WITH IVECTOSOL™

View CEO Update

May 18, 2021

MOUNTAIN VALLEY MD RECEIVES SUCCESSFUL RESULTS FROM BSL-4 COVID-19 CLEARANCE TRIAL ON THREE VARIANTS TESTED WITH IVECTOSOL™

View Media Release

May 11, 2021

MOUNTAIN VALLEY MD PROVIDES UPDATE ON CURRENT TRIALS

View CEO Update

May 11, 2021

MOUNTAIN VALLEY MD PROVIDES UPDATE ON CURRENT TRIALS

View Media Release

May 3, 2021

MOUNTAIN VALLEY MD PROCEEDING WITH PRE-CLINICAL CANCER TRIALS, FILES RELATED CANCER PATENT

View CEO Update

May 3, 2021

MOUNTAIN VALLEY MD PROCEEDING WITH PRE-CLINICAL CANCER TRIALS, FILES RELATED CANCER PATENT

View Media Release

April 20, 2021

MOUNTAIN VALLEY MD HOLDINGS INC. PROCEEDING WITH APPLICATION TO LIST ON THE TSX VENTURE EXCHANGE

View CEO Update

April 20, 2021

MOUNTAIN VALLEY MD HOLDINGS INC. PROCEEDING WITH APPLICATION TO LIST ON THE TSX VENTURE EXCHANGE

View Media Release

March 16, 2021

MOUNTAIN VALLEY MD COMMENCING TRIALS IN BANGLADESH, STRIKING PHARMACEUTICAL PRODUCTION AGREEMENTS

View CEO Update

March 16, 2021

MOUNTAIN VALLEY MD COMMENCING TRIALS IN BANGLADESH, STRIKING PHARMACEUTICAL PRODUCTION AGREEMENTS

View Media Release

March 10, 2021

MOUNTAIN VALLEY MD ACHIEVES SOLUBILIZATION OF SELAMECTIN, FILES TRADEMARK FOR SELACTOSOL™

View CEO Update

March 10, 2021

MOUNTAIN VALLEY MD ACHIEVES SOLUBILIZATION OF SELAMECTIN, FILES TRADEMARK FOR SELACTOSOL™

View Media Release

March 3, 2021

MOUNTAIN VALLEY MD PROCEEDING WITH FDA 505(b)(2) PATHWAY APPLICATION FOR NOVEL IVECTOSOL™

View CEO Update

March 3, 2021

MOUNTAIN VALLEY MD PROCEEDING WITH FDA 505(b)(2) PATHWAY APPLICATION FOR NOVEL IVECTOSOL™

View Media Release

March 1, 2021

MOUNTAIN VALLEY MD COMMENCING HUSBANDRY ANIMAL TRIALS, APPOINTS SEASONED DOCTOR OF VETERINARY MEDICINE TO ADVISORY BOARD

View CEO Update

March 1, 2021

MOUNTAIN VALLEY MD COMMENCING HUSBANDRY ANIMAL TRIALS, APPOINTS SEASONED DOCTOR OF VETERINARY MEDICINE TO ADVISORY BOARD

View Media Release

February 25, 2021

MOUNTAIN VALLEY MD CONFIRMS QUICKSOME™ LICENSE AGREEMENT, FIRST REVENUES

View CEO Update

February 25, 2021

MOUNTAIN VALLEY MD CONFIRMS QUICKSOME™ LICENSE AGREEMENT, FIRST REVENUES

View Media Release

February 22, 2021

MOUNTAIN VALLEY MD TO INCLUDE TESTING OF SOUTH AFRICAN MUTATION IN UPCOMING COVID-19 BSL-4 CLEARANCE WORK

View CEO Update

February 22, 2021

MOUNTAIN VALLEY MD TO INCLUDE TESTING OF SOUTH AFRICAN MUTATION IN UPCOMING COVID-19 BSL-4 CLEARANCE WORK

View Media Release

February 16, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STOCK OPTION GRANT AND WARRANT EXERCISE UPDATE

View CEO Update

February 16, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STOCK OPTION GRANT AND WARRANT EXERCISE UPDATE

View Media Release

February 12, 2021

MOUNTAIN VALLEY MD HOLDINGS TO COMMENCE TRADING ON OTCQB MARKET UNDER TICKER MVMDF

View CEO Update

February 12, 2021

MOUNTAIN VALLEY MD HOLDINGS TO COMMENCE TRADING ON OTCQB MARKET UNDER TICKER MVMDF

View Media Release

February 1, 2021

MOUNTAIN VALLEY MD CONTRACTS TULANE UNIVERSITY FOR ADJUVANT IPV STUDY

View CEO Update

February 1, 2021

MOUNTAIN VALLEY MD CONTRACTS TULANE UNIVERSITY FOR ADJUVANT IPV STUDY

View Media Release

January 27, 2021

MOUNTAIN VALLEY MD PROCEEDING WITH COVID-19 CLEARANCE TRIAL IN LEVEL 4 BIOHAZARD FACILITY

View CEO Update

January 27, 2021

MOUNTAIN VALLEY MD PROCEEDING WITH COVID-19 CLEARANCE TRIAL IN LEVEL 4 BIOHAZARD FACILITY

View Media Release

January 19, 2021

MOUNTAIN VALLEY MD FILES PATENT FOR NOVEL VACCINE DOSE SPARING ADJUVANT

View CEO Update

January 19, 2021

MOUNTAIN VALLEY MD FILES PATENT FOR NOVEL VACCINE DOSE SPARING ADJUVANT

View Media Release

January 14, 2021

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

View CEO Update

January 14, 2021

MOUNTAIN VALLEY MD AWARDED CANADIAN PATENT FOR ITS QUICKSOME™ TECHNOLOGY

View Media Release

January 10, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES APPLICATION FOR OTCQB LISTING IN U.S., PROVIDES UPDATE ON WARRANT EXERCISES

View CEO Update

January 10, 2021

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES APPLICATION FOR OTCQB LISTING IN U.S., PROVIDES UPDATE ON WARRANT EXERCISES

View Media Release

December 28, 2020

MOUNTAIN VALLEY MD COMPLETES STRATEGIC SALE OF SUBSIDIARY, FINALIZING QUICKSOME™ LICENSE AGREEMENT

View CEO Update

December 28, 2020

MOUNTAIN VALLEY MD COMPLETES STRATEGIC SALE OF SUBSIDIARY, FINALIZING QUICKSOME™ LICENSE AGREEMENT

View Media Release

December 24, 2020

MOUNTAIN VALLEY MD FILES FOR ACCELERATION OF PATENT EXAMINATION FOR SOLUBILIZED IVERMECTIN

View CEO Update

December 24, 2020

MOUNTAIN VALLEY MD FILES FOR ACCELERATION OF PATENT EXAMINATION FOR SOLUBILIZED IVERMECTIN

View Media Release

December 22, 2020

MOUNTAIN VALLEY MD HOLDINGS OVERSUBSCRIBES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS

View CEO Update

December 22, 2020

MOUNTAIN VALLEY MD HOLDINGS OVERSUBSCRIBES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS

View Media Release

December 14, 2020

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS, APPOINTMENT OF ADVISOR BOARD MEMBERS, AND PROPOSED DEBT SETTLEMENT

View CEO Update

December 14, 2020

MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES STRATEGIC PRIVATE PLACEMENT OFFERING OF UNITS, APPOINTMENT OF ADVISOR BOARD MEMBERS, AND PROPOSED DEBT SETTLEMENT

View Media Release

December 10, 2020

MOUNTAIN VALLEY MD CONFIRMS 800% INCREASE IN IVERMECTIN ABSORPTION WITH SOLUBILIZATION TECHNOLOGY IN PRE-CLINICAL TRIAL

View CEO Update

December 10, 2020

MOUNTAIN VALLEY MD CONFIRMS 800% INCREASE IN IVERMECTIN ABSORPTION WITH SOLUBILIZATION TECHNOLOGY IN PRE-CLINICAL TRIAL

View Media Release

November 25, 2020

MOUNTAIN VALLEY MD SECURES QUICKSOME™ LICENSE AGREEMENT AND STRATEGIC SALE OF SUBSIDIARY

View CEO Update

November 25, 2020

MOUNTAIN VALLEY MD SECURES QUICKSOME™ LICENSE AGREEMENT AND STRATEGIC SALE OF SUBSIDIARY

View Media Release

November 10, 2020

MOUNTAIN VALLEY MD FILES PATENT TO PROTECT SCIENCE ACHIEVEMENT IN SOLUBILIZATION OF IVERMECTIN WITHOUT ORGANIC SOLVENTS AND ITS APPLICATION TO COVID-19 AND OTHER THERAPIES

View CEO Update

November 10, 2020

MOUNTAIN VALLEY MD FILES PATENT TO PROTECT SCIENCE ACHIEVEMENT IN SOLUBILIZATION OF IVERMECTIN WITHOUT ORGANIC SOLVENTS AND ITS APPLICATION TO COVID-19 AND OTHER THERAPIES

View Media Release

October 2, 2020

MOUNTAIN VALLEY MD PROVIDES SUCCESSFUL QUICKSOME™ SUBLINGUAL PRE-CLINICAL TRIAL DOSING UPDATE

View CEO Update

October 2, 2020

MOUNTAIN VALLEY MD PROVIDES SUCCESSFUL QUICKSOME™ SUBLINGUAL PRE-CLINICAL TRIAL DOSING UPDATE

View Media Release

August 25, 2020

LEADING VACCINE EXPERT JOINS MOUNTAIN VALLEY MD ADVISORY BOARD TO ADVANCE QUICKSOME™ COMMERCIALIZATION

View CEO Update

August 25, 2020

LEADING VACCINE EXPERT JOINS MOUNTAIN VALLEY MD ADVISORY BOARD TO ADVANCE QUICKSOME™ COMMERCIALIZATION

View Media Release

August 7, 2020

MOUNTAIN VALLEY MD SECURES DISTRIBUTION RIGHTS FOR NEW AGRICULTURAL PLANT STIMULANT

View CEO Update

August 7, 2020

MOUNTAIN VALLEY MD SECURES DISTRIBUTION RIGHTS FOR NEW AGRICULTURAL PLANT STIMULANT

View Media Release

August 6, 2020

MOUNTAIN VALLEY MD ANNOUNCES SUCCESSFUL COMPLEXATION OF IVERMECTIN DRUG IN QUICKSOME™ ORAL STRIP AND COMMENCEMENT OF PRE-CLINICAL TRIALS

View CEO Update

August 6, 2020

MOUNTAIN VALLEY MD ANNOUNCES SUCCESSFUL COMPLEXATION OF IVERMECTIN DRUG IN QUICKSOME™ ORAL STRIP AND COMMENCEMENT OF PRE-CLINICAL TRIALS

View Media Release

July 31, 2020

U.S. FOOD AND DRUG ADMINISTRATION (FDA) POLIO LAB CONFIRMS MOUNTAIN VALLEY MD’S QUICKSOME™ TECHNOLOGY SUCCESSFULLY PRESERVES POLIO D ANTIGEN FOR VACCINES

View CEO Update

July 31, 2020

U.S. FOOD AND DRUG ADMINISTRATION (FDA) POLIO LAB CONFIRMS MOUNTAIN VALLEY MD’S QUICKSOME™ TECHNOLOGY SUCCESSFULLY PRESERVES POLIO D ANTIGEN FOR VACCINES

View Media Release

July 28, 2020

MOUNTAIN VALLEY MD HOLDINGS’ SUBSIDIARY COMPLETES ACQUISITION OF COLOMBIAN CANNABIS LICENCE SUITE

View CEO Update

July 28, 2020

MOUNTAIN VALLEY MD HOLDINGS’ SUBSIDIARY COMPLETES ACQUISITION OF COLOMBIAN CANNABIS LICENCE SUITE

View Media Release

July 17, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES INTELLECTUAL PROPERTY ASSET TRANSFER, SOLIDIFIES QUICKSOME TECHNOLOGY

View CEO Update

July 17, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES INTELLECTUAL PROPERTY ASSET TRANSFER, SOLIDIFIES QUICKSOME TECHNOLOGY

View Media Release

May 4, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES NEW CFO, NEW BOARD MEMBER AND TRANSITION OF PREVIOUS CFO TO ADVISORY ROLE

View CEO Update

May 4, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES NEW CFO, NEW BOARD MEMBER AND TRANSITION OF PREVIOUS CFO TO ADVISORY ROLE

View Media Release

March 17, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. PROVIDES UPDATE ON INTELLECTUAL PROPERTY ASSETS, COMPLETES SHARES FOR DEBT TRANSACTION AND GRANT OF OPTIONS

View CEO Update

March 17, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. PROVIDES UPDATE ON INTELLECTUAL PROPERTY ASSETS, COMPLETES SHARES FOR DEBT TRANSACTION AND GRANT OF OPTIONS

View Media Release

March 3, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. COMMENCES TRADING ON CSE UNDER TICKER “MVMD”

View CEO Update

March 3, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. COMMENCES TRADING ON CSE UNDER TICKER “MVMD”

View Media Release

February 26, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES APPROVAL OF CSE LISTING

View CEO Update

February 26, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. ANNOUNCES APPROVAL OF CSE LISTING

View Media Release

February 24, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES REVERSE TAKEOVER TRANSACTION

View CEO Update

February 24, 2020

MOUNTAIN VALLEY MD HOLDINGS INC. COMPLETES REVERSE TAKEOVER TRANSACTION

View Media Release

We are a biotech company working on solving critical healthcare problems, so that people and animals around the world are free to live their best life.

Mountain Valley MD - "Infinite Possibility"

Mountain Valley MD - "Infinite Possibility"

Infinite Possibility.

Mountain Valley MD News

Stay up to date on all Mountain Valley MD News and Videos.

Subscribe To Updates

Mountain Valley MD Holdings Completes Pre-clinical Pharmacokinetic Study for Soluvec

Mountain Valley MD Holdings Completes Pre-clinical Pharmacokinetic Study for Soluvec

June 28, 2022

Mountain Valley MD Holdings Completes Pre-clinical Pharmacokinetic Study for Soluvec

Read Article View Image

June 28, 2022

Mountain Valley MD Holdings Completes Pre-clinical Pharmacokinetic Study for Soluvec

Read Update Read Article Read Press Release View Image

May 12, 2022

DIGITAL I WIRE - Is Ivermectin a Cancer Solution

Read Update Read Article Read Press Release View Image

April 28, 2022

MVMD Broad Business Update

Read Update Read Article Read Press Release View Image

March 16, 2022

MVMD Welcomes Dr. Elizabeth Norton to Advisory Role / Cold Chain and Vaccine Progress

Read Update Read Article Read Press Release View Image

January 13, 2022

MVMD Update - Capitalizing on 2022!

Read Update Read Article Read Press Release View Image

November 15, 2021

MVMD CEO, Dennis Hancock interviewed on Canada's Podcast

Read Update Read Article Read Press Release View Image

October 14, 2021

4 top biotech stocks to watch in October 2021

Read Update Read Article Read Press Release View Image

September 29, 2021

MVMD - AGM Business Presentation

Read Update Read Article Read Press Release View Image

August 31, 2021

Anti-parasitic drug discovered in 1975 could be ‘game-changer’ in fight against cancer

Read Update Read Article Read Press Release View Image

August 27, 2021

Mountain Valley MD stock uplists to the OTCQX Best Market as it eyes US senior exchange listing

Read Update Read Article Read Press Release View Image

August 13, 2021

CHCH - Women in Science

Read Update Read Article Read Press Release View Image

July 21, 2021

MVMD CEO insight on Moderna inclusion in S&P Index

Read Update Read Article Read Press Release View Image

July 21, 2021

Dennis Hancock of Mountain Valley MD: In Light Of The Pandemic, Here Are The 5 Things We Need To Do To Improve The US Healthcare System

Read Update Read Article Read Press Release View Image

July 14, 2021

This Entrepreneur Is On A Mission To Tackle Global Health Challenges

Read Update Read Article Read Press Release View Image

July 12, 2021

Mountain Valley MD Pursues Ambitious Initiatives, Including Partnership With FDA

Read Update Read Article Read Press Release View Image

July 9, 2021

MVMD Interview on Cold Chain Results & Broad Corporate Update

Read Update Read Article Read Press Release View Image

July 7, 2021

CEO Update: MVMD Announces Results from FDA Cold Chain Evaluation

Read Update Read Article Read Press Release View Image

June 25, 2021

Emerging Biotech Company MVMD Looks To Take On Cancer, COVID-19 And More

Read Update Read Article Read Press Release View Image

June 25, 2021

A Promising COVID-19 Treatment May Succeed Where Vaccines Can't Reach

Read Update Read Article Read Press Release View Image

June 17, 2021

Solubilised ivermectin improves drug delivery

Read Update Read Article Read Press Release View Image

May 28, 2021

The Only Reason You Might Not Need a COVID Booster Shot, Doctors Say

Read Update Read Article Read Press Release View Image

May 19, 2021

MVMD CEO Dennis Hancock Talks Ivectosol Results, The Politicization Of Ivermectin, And More

Read Update Read Article Read Press Release View Image

May 18, 2021

MVMD Coverage by Industry Wired - 10 US Pharma Stocks To Buy & Hold During COVID-19

Read Update Read Article Read Press Release View Image

May 18, 2021

MVMD Coverage by BioWorld™

Read Update Read Article Read Press Release View Image

May 18, 2021

CANCER INNOVATION – MOUNTAIN VALLEY MD

Read Update Read Article Read Press Release View Image

May 14, 2021

MVMD Coverage by ZeroHedge

Read Update Read Article Read Press Release View Image

May 7, 2021

MVMD’s CEO interviewed on the Dahlia Kurtz Show

Read Update Read Article Read Press Release View Image

May 6, 2021

Mountain Valley MD CEO thinks investors should be excited about the company’s ability to bring technology into commercialization this year

Read Update Read Article Read Press Release View Image

May 5, 2021

Mountain Valley MD ( MVMD:CSE ) Proceeding With Pre-Clinical Cancer Trials & Files Related Patent

Read Update Read Article Read Press Release View Image

May 4, 2021

Mountain Valley MD preparing to start pre-clinical trial for use of ivermectin to target cancer

Read Update Read Article Read Press Release View Image

May 4, 2021

Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights

Read Update Read Article Read Press Release View Image

May 4, 2021

Mountain Valley MD files patent and begins pre-clinical trials to enter USD $100 billion cancer drug market

Read Update Read Article Read Press Release View Image

May 2, 2021

Covid crisis: Should India be a warning for other countries? MVMD Weighs In.

Read Update Read Article Read Press Release View Image

April 27, 2021

MVMD’s CEO interviewed on the Shaun Proulx Show.

Read Update Read Article Read Press Release View Image

April 22, 2021

Mountain Valley MD (MVMD.C) CEO, Dennis Hancock's & Ivermectin trials update (Ep 50) FG/JV

Read Update Read Article Read Press Release View Image

March 20, 2021

Q&A With Mountain Valley MD's CEO & President, Dennis Hancock

Read Update Read Article Read Press Release View Image

March 18, 2021

This Small Company Has Plans to Change the World! Mountain Valley MD Holdings | MVMDF | MVMD

Read Update Read Article Read Press Release View Image

March 18, 2021

Mountain Valley MD (MVMD.C) president and CEO, Dennis Hancock's latest update (Ep 39) FG/JV

Read Update Read Article Read Press Release View Image

March 16, 2021

Mountain Valley about to start animal trials in Bangladesh while also beginning production pipeline

Read Update Read Article Read Press Release View Image

March 10, 2021

Mountain Valley MD Achieves Solubilization of Selamectin, Files Trademark for Selactosol™

Read Update Read Article Read Press Release View Image

March 10, 2021

Mountain Valley MD takes major step forward achieving Solubilization of Selamectin

Read Update Read Article Read Press Release View Image

MORE LIFE.

Mountain Valley MD is a specialized collective of scientists, doctors and entrepreneurs solving some of the world’s most significant healthcare problems. We are united in our mission for a world where every human, husbandry and companion animal can live their best life, free from the tragedies of disease.
‍
We are bringing our vision to life with the powerful combination of science and the belief that the world can change. It is the formula that is fundamental to how and why we operate, every day. And it is what drives the innovation of our industry-leading vaccine, pharmaceutical and nutraceutical technologies.

“We believe this discovery to be a breakthrough that will enable the efficacy needed to treat respiratory infections such as COVID-19, influenza and tuberculosis by enabling the drug deposition into the airways and lungs through aerosol formulations and pulmonary delivery.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“This is the best interview Agoracom has done in the last ten years. If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.”

- George Tsiolis, President of Agoracom

“Embedding Mountain Valley MD’s Quicksome™️ technology into our unique mushroom product formulations has allowed us to create a product line that we believe will be unmatched in its efficacy in the marketplace... The initial consumer testing with our energy and sleep products has been very well received. The precision of this delivery technology allows us to build the functional mushroom business out while simultaneously pursuing a leadership position in the rapidly emerging psychedelic space.”

- Dr. Sanjeev Goel, Chief Medical Officer at Circadian Wellness and Founder of Peak Human Labs.

“This breakthrough is a major game-changer for the future potential administration of Ivermectin, and perhaps other drug and vaccine applications. Applied to Ivermectin, Mountain Valley’s Quicksome technology greatly improved its therapeutic potential.”

- Benjamin Smith, The Dales Report

“The extrapolation of this technology achievement across multiple viral applications could be very significant and has the potential to positively impact human and animal health globally.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“Our study will evaluate the ability of MVMD’s new porous aluminum nanostructures to adjuvant injected IPV, promote dose-sparing, and therefore lower costs, and facilitate mucosal and herd immunity when compared to IPV.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“MVMD has developed a tablet that dissolves easily, with a fraction of the dose, of wonder drug Ivermectin.”

- Jackie Cameron, BizNews

“A needle-free, cost-effective, polio vaccine could be a major step towards global polio eradication. Mountain Valley MD’s Quicksome™ technology has already proven its ability to stabilize and preserve the Inactivated Poliovirus Vaccine (IPV) and I believe that this technology holds great promise in finally delivering a needle-free effective sublingual polio vaccine and probably many other globally needed vaccines as well.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“The FDA’s Polio D Antigen preservation results demonstrate that Mountain Valley MD’s proprietary and patented Quicksome™ low temperature strip manufacturing technology can be successfully applied to heat labile vaccines, complex proteins such as insulin or glucagon, peptides and other molecules and constructs that are sensitive to heat and oxidation.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“We designed the study with the goal of providing the first in vivo proof of enhanced COVID-19 viral clearance ability using both the oral sublingual product and the intramuscular injection product using MVMD’s Quicksol™ technology.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

“With encouraging FDA Polio Lab validation, Mountain Valley MD is continuing work on development of our proprietary vaccine adjuvants for Polio and the necessary pre-clinical trials to demonstrate the unprecedented impact of our Quicksome™ technology.”

- Dennis Hancock, President & CEO of Mountain Valley MD

“MVMD takes existing vaccines and drugs – and delivers them better. Both into the body and by transportation to the world. Way better.”

- George Tsiolis, President of Agoracom

“MVMD’s technology showed greater pharmacokinetic performance, more rapid onset times, with greater drug distribution and stability in the canines trialled—at 1/5 the dosages compared to existing oral and subcutaneous injection solutions.”

- Benjamin Smith, The Dales Report

“For decades scientists have been working to solve the problem of vaccine instability and cold chain distribution with little progress. Approaches such as micro-needle applications, lyophilization, spray drying, and others have not reached commercialization due to problems of complexity, cost, and long-term stability challenges.”

- Mike Farber, Director of Life Sciences at Mountain Valley MD, Inventor

“The transgenic mice model was selected to specifically enable preclinical evaluation of the potential therapeutics and monoclonal antibodies and molecular-based therapeutics as they apply to COVID-19 treatments.”

- Dr. John Clements, Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine

Subscribe to Updates from MVMD

Stay plugged in on everything MVMD.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

*By Clicking "Sign Up" You agree to Mountain Valley MD's Privacy Policy